How Singapore’s AI ecosystem and healthcare expertise drive MedTech innovation

Recent breakthroughs in artificial intelligence (AI) have drastically changed the medical technology (MedTech) industry. AI powers new diagnostic tools that catch diseases earlier, automate tedious regulatory paperwork and transform traditional medical devices into smart, connected healthcare solutions.

Recent research from APACMed and Bain & Company reveals three major shifts in MedTech:

• AI is making products smarter through advanced algorithms.
  Diagnostic tools now process medical images faster and more accurately than before. Smart algorithms create personalised treatment plans based on individual patient data. Connected devices provide real-time health monitoring and insights.
• AI is driving productivity gains across the MedTech value chain.
  Companies using AI in their regulatory submissions get therapies to market up to 50 per cent faster. Manufacturing facilities are using AI quality control systems to maintain high standards with less human error. Supply chains are running more efficiently with AI-powered demand forecasting.
• AI is enabling new business revenue streams.
  The ongoing shift to technology-enabled services is opening up new revenue streams for MedTech companies. Many now offer comprehensive platforms combining devices, data analytics, and remote monitoring capabilities.

With a robust talent pool and supportive ecosystem enablers, Singapore stands out as a choice location for companies to harness the potential of AI in powering the next phase of MedTech growth.

Singapore is growing its pool of “bilingual talent” to transform healthcare using AI

Building “bilingual talent” — professionals who can combine both healthcare domain knowledge and deep technical AI skills — is central to helping companies develop and deliver AI-driven healthcare solutions. Current data shows just 10 per cent of MedTech professionals in Asia-Pacific (APAC) possess this vital combination of skills. Clinical teams struggle to communicate requirements to AI specialists while technical teams find it difficult to align solutions with healthcare workflows. The shortage affects companies at every stage - from development through deployment - and makes it harder for companies to scale new AI solutions.

Singapore is actively addressing this global gap through initiatives such as the AI Apprenticeship Programme and facilitating partnerships between local institutes of higher learning with global tech companies. One such example is the IBM SkillsBuild programme with Republic Polytechnic and Singapore Polytechnic, which seeks to help learners develop valuable new skills and access career opportunities. Such initiatives provide hands-on training, facilitate collaborative research projects, and build industry-relevant capabilities that give Singapore-based companies an edge in AI innovation across various sectors, including MedTech.
 

Singapore’s ecosystem advantage in advancing MedTech AI

To harness the full potential of AI for MedTech innovation in the region, data is key. However, many Asian genetic profiles remain under-represented in current genomic databases, despite Asia accounting for 60% of the global population. This limits the development of new therapies, especially for diseases that are more prevalent among these communities.

Often referred to as a microcosm of Asia, Singapore’s multi-ethnic population – comprising Chinese, Malay and Indian races – represents nearly 80% of the genetic variation found in Asia. To improve representation of Asian populations in global genomic research and support more inclusive precision medicine worldwide, Singapore launched its National Precision Medicine (NPM) initiative — a 10-year national effort to integrate genomic, clinical, lifestyle, and environmental data from up to 10% of its population by 2031.

The aim is to improve health outcomes, enable research, and unlock economic value. Rolled out in phases, the initiative began with building a national reference genome and is now expanding clinical applications and population-level sequencing through programmes like SG100K. SG100K aims to sequence and analyse the whole genomes of 100,000 Singaporeans from diverse ethnic backgrounds to strengthen the country’s biomedical research and clinical innovation capabilities.

Singapore is also enabling access to robust healthcare data, through initiatives like the TRUST platform. This facilitates secure data sharing between private and public institutions, which can help to accelerate innovation while upholding stringent standards of privacy and data governance. Recent examples include risk prediction for congenital hearing loss, cancer risk modelling, respiratory disease research using administrative data, and studies on genetic variants in diverse Asian populations.

These initiatives enable MedTech companies to use AI to gain insights into Asia-specific diseases and develop targeted innovations to improve population health and patient outcomes.

Singapore’s commitment to AI leadership is further demonstrated by its refreshed National AI Strategy, that will see Singapore invest more than S$1 billion over the next five years into AI compute, talent and industry development and triple the number of AI practitioners to 15,000 by training locals and hiring from overseas. MedTech companies can also tap on the city state’s Sectoral AI Centre of Excellence for Manufacturing (AIMfg) for support on deploying and scaling up AI solutions.
 

Singapore has already emerged as a powerhouse for AI-enabled MedTech innovation and operations

Companies advancing AI in MedTech in Singapore have already found success, whether they are MedTech multinational corporations (MNCs) or start-ups and small and medium-sized enterprises (SMEs).

Agilent Technologies is a prime example. Its best-in-class facility in Singapore has been recognised as a leader in AI-enabled manufacturing for scientific instruments by the World Economic Forum as part of its Global Lighthouse Network. Agilent’s use of AI algorithms to learn from previous test results, identify patterns, and maintain automated tests has led to a 23 per cent improvement in work cycle times. Additionally, Agilent’s use of AI-powered tools has helped to reduce its production downtime by 51 per cent.

Singapore's vibrant ecosystem has also catalysed the growth of breakthrough MedTech AI innovations from local enterprises. For example:

• KroniKare’s AI-powered wound care scanner: This solution uses AI to provide fast, non-invasive assessments of chronic wounds, significantly improving efficiency and accuracy in wound management.
• NDR Medical Technology’s automated needle targeting system: A precise surgical targeting system that enhances biopsy and ablation procedures, this AI-driven tool reduced procedure time, improves clinical outcomes and patient safety.
   

Why should MedTech companies partner with Singapore?

Singapore has invested over two decades in its biomedical sciences industry and has built a comprehensive, end-to-end ecosystem that spans research and development, high-value manufacturing, and commercial headquarters (HQs). The city-state is home to the top 30 MedTech MNCs, many of which base their regional leadership in Singapore alongside their best-in-class manufacturing facilities here, producing more than S$19 billion of high value medical devices such as cardiac implants and contact lenses every year. More than 20 of these MNCs operate Research and Development (R&D) centres here, conducting regional upstream clinical needs identification, software and digital development, and product and process innovation.

For MedTech companies looking to leverage AI in healthcare, Singapore offers three key advantages:

1. Access to specialised talent: Over 17,000 employees work in the MedTech sector across more than 400 global and local enterprises. The country's strong emphasis on interdisciplinary education and collaboration between MedTech firms, universities, and research institutions ensures that its healthcare talent is not just technically skilled, but also well-equipped to apply AI across MedTech research, product development, and manufacturing.
2. Robust infrastructure for testing and scaling solutions: The country's advanced healthcare data infrastructure and supportive regulatory environment make it an ideal sandbox for piloting AI solutions. Companies benefit from strong intellectual property protection and established trade networks that facilitate access to APAC markets.
3. Strong government support: The government actively supports AI development through research partnerships, grants, and clear regulatory frameworks. Under the current national five-year Research, Innovation and Enterprise (RIE) 2025 plan, the government committed to sustaining investments in R&D to the tune of S$28 billion, across four strategic domains including Human Health and Potential and Smart Nation and Digital Economy. The next five-year RIE plan is currently being developed.

MedTech companies working with Singapore will gain access to a thriving ecosystem designed to support AI innovation. With its skilled workforce and advanced infrastructure, Singapore enables firms to develop, test and scale solutions that address regional healthcare needs while meeting global standards.

Download the “Establishing the Asia-Pacific Region as a MedTech AI Capability Hub” by APACMed and Bain & Company to explore how Singapore can partner you to innovate, strengthen supply chain resilience and pursue growth.